The activity of garenoxacin was investigated in rats with experimental endocarditis due to staphylococci and viridans group streptococci (VGS). The staphylococci tested comprised one ciprofloxacin-susceptible and methicillin-susceptible Staphylococcus aureus (MSSA) isolate (isolate 1112), one ciprofloxacin-susceptible but methicillin-resistant S. aureus (MRSA) isolate (isolate P8), and one ciprofloxacin-resistant mutant (grlA) of P8 (isolate P8-4). The VGS tested comprised one penicillin-susceptible isolate and one penicillin-resistant isolate (Streptococcus oralis 226 and Streptococcus mitis 531, respectively). To simulate the kinetics of drugs in humans, rats were infused intravenously with garenoxacin every 24 h (peak and trough levels in serum, 6.1 and Gram-positive bacteria are major causes of both communityand hospital-acquired severe infections. Over the years, grampositive pathogens have progressively developed resistance against almost all of the available antibacterial agents. For instance, therapeutic options for methicillin-resistant Staphylococcus aureus (MRSA) are often limited to glycopeptides such as vancomycin or, alternatively, to the novel agents quinupristin-dalfopristin and linezolid (3). However, vancomycinintermediate and highly resistant clinical MRSA isolates have recently been described in several countries (5, 6, 23), jeopardizing the use of glycopeptides. In parallel, viridans group streptococci (VGS), which are the leading cause of infectious endocarditis, are becoming resistant to beta-lactams and numerous other drugs (13). The emergence of bacterial resistance to most classes of antibiotics has stimulated the search for new antimicrobial drugs.
Gram-positive bacteria are major causes of both communityand hospital-acquired severe infections. Over the years, grampositive pathogens have progressively developed resistance against almost all of the available antibacterial agents. For instance, therapeutic options for methicillin-resistant Staphylococcus aureus (MRSA) are often limited to glycopeptides such as vancomycin or, alternatively, to the novel agents quinupristin-dalfopristin and linezolid (3) . However, vancomycinintermediate and highly resistant clinical MRSA isolates have recently been described in several countries (5, 6, 23) , jeopardizing the use of glycopeptides. In parallel, viridans group streptococci (VGS), which are the leading cause of infectious endocarditis, are becoming resistant to beta-lactams and numerous other drugs (13) . The emergence of bacterial resistance to most classes of antibiotics has stimulated the search for new antimicrobial drugs.
Garenoxacin (BMS-284756) is a novel des-fluoro(6)-quinolone that appears to be very active against multiresistant S. aureus strains and penicillin-resistant streptococci (20) . Therefore, garenoxacin may be particularly well suited as an agent that targets both Staphylococcus spp. and Streptococcus spp. Furthermore, garenoxacin seems to be active against many quinolone-resistant gram-positive cocci (24) .
The aims of the experiments described below were to determine both the activity of garenoxacin and the risk of the emergence of resistance in vitro and in a rat model of experimental endocarditis. Rats with catheter-induced aortic vegetations were infected with either ciprofloxacin-susceptible or ciprofloxacin-resistant S. aureus or penicillin-susceptible or penicillin-resistant VGS. Infected rats were treated with (i) garenoxacin; (ii) the control quinolone levofloxacin, a new quinolone recently introduced in the clinical setting; (iii) flucloxacillin or vancomycin, the reference drugs for the treatment of endocarditis due to methicillin-susceptible S. aureus (MSSA) and MRSA, respectively, in humans (31); or (iv) ceftriaxone, a recommended alternative for the treatment of endocarditis due to VGS in humans (31) . The rats were treated with the drugs so that the kinetics in the serum of rats simulated those in the serum of humans.
MATERIALS AND METHODS
Microorganisms and growth conditions. The test organisms (Table 1) were clinical isolates that were previously used in studies of experimental endocarditis (15) (16) (17) (18) . The staphylococci included one ciprofloxacin-susceptible MSSA isolate (isolate 1112), one ciprofloxacin-susceptible MRSA isolate (isolate P8), and one first-level ciprofloxacin-resistant mutant of P8 (Ser803Phe in grlA), MRSA isolate P8-4. The isolates of VGS tested included one penicillin-susceptible isolate and one penicillin-resistant isolate (Streptococcus oralis 226 and Streptococcus mitis 531, respectively). Unless otherwise stated, the staphylococci were grown at 35°C in tryptic soy broth (Difco Laboratories, Detroit, Mich.) supplemented with 2% NaCl with aeration in a shaking incubator at 120 rpm. VGS were grown in brain heart infusion (Difco) without aeration. All the organisms were plated on Columbia agar plates (Becton Dickinson Microbiology Systems, Cockeysville, Md.) supplemented with 4% blood.
Antibiotics. Garenoxacin was provided by Bristol-Myers Squibb (Syracuse, N.Y.). Levofloxacin was purchased from Aventis Pharma AG (Zurich, Switzerland), ciprofloxacin was purchased from Bayer AG (Wuppertal, Germany), vancomycin was purchased from Elli Lilly (Geneva, Switzerland), and ceftriaxone was purchased from Roche Pharma (Reinach, Switzerland).
Susceptibility testing and time-kill studies. MICs were determined by a previously described broth macrodilution method (26) with a final inoculum of 10 5 to 10 6 CFU/ml. For the time-kill studies, series of flasks containing fresh prewarmed medium were inoculated with ca. 10 6 CFU/ml (final concentration) from an overnight culture of bacteria, and the bacteria were further incubated at 35°C. Immediately after inoculation, the antibiotics were added to the flasks at final concentrations that approximated the peak and trough levels of antibiotics produced in the serum of humans with therapeutic doses of the drugs (see Results). The respective concentrations were 5 and 1 mg/liter for garenoxacin, 5 and 1 mg/liter for levofloxacin, 100 and 10 mg/liter for flucloxacillin, 40 and 5 mg/liter for vancomycin, and 200 and 20 mg/liter for ceftriaxone.
Samples were removed from the tubes just before and at various times after antibiotic addition, serially diluted, and plated onto blood agar for colony count determinations. Antibiotic carryover was minimized as described previously (15) (16) (17) (18) . Each time-kill experiment was performed on two independent occasions.
Production of endocarditis and installation of the infusion pump. Sterile aortic vegetations were produced in rats by the insertion of a polyethylene catheter (Guerbet Biomédical, Louvres, France) via the right carotid artery across the aortic valve. The catheter was secured with a silk ligature and was left in place for the remainder of the experiment (22) . Close by, an intravenous (i.v.) line was inserted via the jugular vein into the superior vena cava and connected to a programmable infusion pump (Pump 44; Harvard Apparatus, Inc., South Natick, Mass.) to deliver the antibiotics (19) . The pump was set to deliver a volume of 0.1 ml of saline per h to keep the catheter open until the onset of therapy. No i.v. lines were placed in the control animals.
Bacterial endocarditis was induced 24 h after catheterization by i.v. challenge of the animals with either 10 5 CFU of the S. aureus isolates or 10 7 CFU of the VGS. These inocula were 10 and 100 times larger than the minimum inoculum producing endocarditis in 90% of control rats infected with S. aureus and VGS, respectively (15) (16) (17) (18) . A higher inoculum size for VGS than for S. aureus was used in order to obtain similar colony counts in the vegetations at the onset of therapy (see Results), as VGS produce much less severe disease than S. aureus. The absence of an i.v. line in the controls did not affect the frequency of infection of these animals.
Antibiotic treatment of experimental endocarditis. Groups of 10 to 12 rats were randomized to receive antibiotics at changing flow rates, in order to simulate the kinetics of the drug in the serum of humans during treatment with (i) 400 mg of garenoxacin orally every 24 h (21; C. Stewart, D. Gajjar 24 h. Control rats (9 to 10 animals) received no therapy. Treatment was started 12 h after inoculation in the case of S. aureus and 24 h after inoculation in the case of VGS and lasted for 3 and 5 days, respectively. Such treatment lengths allowed for better discrimination of the activities of the quinolones against such bacteria (15) (16) (17) (18) .
Pharmacokinetic studies. The concentrations of the antibiotics in serum were determined on day 2 of therapy for groups of three to six uninfected or infected rats. Blood was drawn by puncturing the periorbital sinuses of the animals (one puncture per animal) at several time points during and after antibiotic administration. The concentrations only of garenoxacin in cardiac vegetations were determined on day 2 of therapy by a previously described method (18) . The concentrations were determined in three to four rats at the time of the peak and trough levels of garenoxacin in serum. Antibiotic concentrations were determined by an agar diffusion assay with antibiotic medium 1 (Difco) by using Bacillus subtilis ATCC 6633 as the indicator organism for garenoxacin, levofloxacin, and vancomycin and Escherichia coli ATCC 25922 as the indicator organism for ceftriaxone. The diluent was pooled rat serum. The limits of detection of the assays were 0.08 mg/liter for garenoxacin, 0.15 mg/liter for levofloxacin, 0.6 mg/liter for vancomycin, and 3 mg/liter for ceftriaxone. The linearities of the standard curves were assessed by using a regression coefficient of Ն0.996, and intraplate and interplate variations were Յ10%. The areas under the serum concentration-time curves (AUCs) from time zero to 24 h (AUC 0-24 s) for garenoxacin and levofloxacin was calculated by the trapezoidal summation method.
Evaluation of infection. Control rats were killed at the time of treatment onset, i.e., 12 and 24 h after inoculation with S. aureus and VGS, respectively, in order to determine both the frequency and the severity of valve infection at the start of therapy. Treated rats were killed 12 h after the trough level of the last dose of any of the test drugs was achieved. At that time no residual antibiotic could be detected in the blood. Vegetations, blood, and spleens were cultured as described previously (15) (16) (17) (18) . Only rats that received at least two-thirds of the treatment were evaluated for bacterial counts in the vegetations. Bacterial densities in the organs were expressed as log 10 CFU per gram of tissue. The processing of tissue homogenates allowed detection of Ն2 log 10 CFU/g of vegetation. For statistical comparisons culture-negative vegetations were considered to contain 2 log 10 CFU/g.
Detection of emergence of antibiotic resistance in vivo.
To detect the emergence of quinolone-resistant bacterial derivatives during therapy for endocarditis, 0.1-ml portions of each undiluted vegetation homogenate from animals treated with either garenoxacin or levofloxacin were plated in parallel on plain agar plates and on agar plates supplemented with the test drug at two or four times the MIC. In addition, standard MIC determinations were also performed for bacteria which grew from vegetations on antibiotic-free agar. Ten to 100 colonies were pooled and grown in broth cultures, and the MICs for the colonies were determined as described above. This screening was not performed with flucloxacillin-, vancomycin-, and ceftriaxone-treated animals.
Selection for garenoxacin and levofloxacin resistance in vitro. To more accurately evaluate the risk of selection for quinolone resistance by these two drugs, the following additional tests were performed. First, large inocula (ca. 5 ϫ 10 9 CFU) of the test S. aureus and VGS isolates were spread on agar plates containing increasing concentrations of antibiotics (17) . The drug concentrations were determined in multiples of the MICs to ensure that the antibiotic pressure applied to the organisms was comparable between the two drugs. The plates were then incubated for 48 h at 35°C before the colonies were counted.
Second, selection for quinolone resistance was also performed in broth cultures by exposing bacteria to stepwise increasing concentrations of either garenoxacin or levofloxacin, as described previously (15, 17) .
Statistical analysis. The incidences of valve infection were compared by Fisher's exact test. In certain analyses, differences between residual bacterial densities in the vegetations were compared by the one-way analysis of variance with Bonferroni's correction for multiple comparisons procedure. Differences were considered significant when P was Ͻ0.05 by use of two-tailed significance levels.
RESULTS
In vitro drug susceptibility. Table 1 indicates that garenoxacin was 4 to 16 times more active than levofloxacin against the S. aureus and VGS isolates used in this study. Regarding the control drugs used in vivo, both MSSA and MRSA were susceptible to vancomycin, and penicillin-resistant strain S. mitis 531 was cross-resistant to ceftriaxone. Time-kill curves. At concentrations mimicking both the peak level (5 mg/liter) and the trough level (1 mg/liter) in human serum, garenoxacin caused a Ն3-log CFU/ml decrease in the viable counts of all three staphylococci within 24 h. In contrast, the peak concentration (5 mg/liter) and the trough concentration (1 mg/liter) of levofloxacin in serum were effective only against the two ciprofloxacin-susceptible staphylococci and notably failed to kill the grlA mutant MRSA P8-4.
Both garenoxacin and levofloxacin were effective against VGS (Ͼ3-log CFU/ml decrease in viable counts within 24 h) at peak and trough concentrations. In contrast, concentrations mimicking both the peak level (200 mg/liter) and the trough level (20 mg/liter) of ceftriaxone in human serum were bactericidal against penicillin-susceptible isolate S. oralis 226 but not penicillin-resistant isolate S. mitis 531. Otherwise, the control drugs used in vivo killed their respective target organisms; i.e., flucloxacillin killed MSSA 1112 and vancomycin killed MRSA (data not presented).
Pharmacokinetic studies. The peak (1 h) and trough (24 h) concentrations (mean Ϯ standard deviation for 9 to 15 individual animals for each drug) were (i) 6.1 Ϯ 0.9 and 1.0 Ϯ 0.6 mg/liter, respectively, for garenoxacin and (ii) 7.3 Ϯ 0.2 and 1.5 Ϯ 0.4 mg/liter, respectively for levofloxacin. The AUC 0-24 s for garenoxacin and levofloxacin were 63.4 and 55.6 mg ⅐ h/liter, respectively, i.e., very close to the values reported for these drugs in humans (7, 8, 21 ; Stewart et al., 41st ICAAC). The levels of intravegetation penetration of garenoxacin, expressed as the percentage of the drug concentration measured in the vegetation compared to the concentration measured in the serum of four individual animals, were 59% (range, 56 to 62%) at the peak concentration and 67% (range, 53 to 69%) at the trough concentration. For comparison, the level of intravegetation penetration for the controls treated with levofloxacin in the same model in retrospective experiments was 90.5% (range, 75 to 113%) (15) . This difference is probably related to the different levels of protein binding.
The kinetics of flucloxacillin, vancomycin, and ceftriaxone in human serum were simulated in rats as described previously (15, 17, 18) .
In vivo experiments. (i) Garenoxacin treatment of experimental endocarditis due to ciprofloxacin-susceptible MSSA and MRSA. Figure 1 indicates that both garenoxacin and levofloxacin were successful treatments for valve infections due to the two ciprofloxacin-susceptible S. aureus isolates (P Ͻ 0.05 versus the results for untreated controls; P was not significant between groups). The two drugs were as effective as the control treatment with either flucloxacillin or vancomycin. No treatment failures were due to drug-resistant derivatives. The blood and spleens of all untreated controls (18 of 18) killed at the start of therapy were positive by culture. In contrast, none of the organs of the treated rats were positive by culture after the end of therapy. Mortality during treatment was equally distributed. Overall, the rates of mortality were 3 of 22 (13%), 3 of 18 (16%), 2 of 11 (18%), and 1 of 9 (11%) among the animals in the groups treated with garenoxacin, levofloxacin, flucloxacillin, and vancomycin, respectively. All these rats had sterile vegetations, so death might have been due to complications from the operation itself.
(ii) Garenoxacin treatment of experimental endocarditis due to ciprofloxacin-resistant grlA mutant MRSA P8-4. Figure  2 indicates that garenoxacin remained very effective against MRSA P8-4. Moreover, no garenoxacin-resistant derivatives were detected in the few animals that had treatment failures. In contrast, levofloxacin was totally inactive, and staphylococcal variants with decreased levofloxacin susceptibilities (MICs, 8 to Ͼ32 mg/liter) were observed in four of six animals with treatment failures. The blood and spleens of all the garenoxacin-treated animals were negative by culture. The blood and spleens of few animals (2 of 11) treated with vancomycin were 
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on July 9, 2017 by guest http://aac.asm.org/ positive by culture. In contrast, the blood and spleens of all levofloxacin-treated rats were positive by culture and harbored bacteria at densities similar to those observed in the blood and spleens of the untreated controls (data not presented). The rates of mortality during therapy were 10% (1 of 10 animals) with garenoxacin, 16% (1 of 6 animals) with levofloxacin, and 9% (1 of 11 animals) with vancomycin. All three rats that died remained infected and had colony counts in vegetations similar to those in infected animals that remained alive.
(iii) Garenoxacin treatment of experimental endocarditis due to penicillin-susceptible and penicillin-resistant VGS. Figure 3 indicates that treatment with garenoxacin once a day was uniformly active against the two test isolates of VGS, irrespective of their penicillin susceptibility phenotype (P Ͻ 0.05 compared to the results for the control rats). The activity of garenoxacin was equivalent to that of standard treatment with ceftriaxone against penicillin-susceptible isolate S. oralis 226, and garenoxacin was more effective than ceftriaxone against penicillin-resistant isolate S. mitis 531 (P Ͻ 0.05). In contrast, levofloxacin was ineffective against both organisms, as was observed previously (15) in this infection model. Importantly, treatment failures in either the garenoxacin group or the levofloxacin group were not due to resistant derivatives. As in the experiments with the staphylococci, the spleens and blood of all control rats (20 of 20) killed at the start of therapy were positive by culture. The spleens and blood of none of the rats treated with either garenoxacin or levofloxacin were positive by culture. On the other hand, the organs of few rats (2 of 14) infected with penicillin-resistant isolate S. mitis 531 and treated with ceftriaxone were positive by culture. Overall, the rates of mortality were 4 of 26 (15%) animals in the garenoxacin group, 8 of 19 (42%) animals in the levofloxacin group (P ϭ 0.08 versus the results for the garenoxacin group), and 4 of 17 (22%) animals in the ceftriaxone group. None of the rats in the garenoxacin group that died was infected. In contrast, six of eight animals in the levofloxacin group that died and two of four animals in the ceftriaxone that died remained infected at the same level as infected animals that remained alive.
Relation between pharmacodynamic parameters, therapeutic efficacy, and selection for resistance in vivo. Table 2 compares the in vivo results with the pharmacodynamic parameters recently proposed by Andes and Craig (1) to predict the success of fluoroquinolone treatment for experimental endocarditis. Those investigators suggested that maximum concentration of drug in serum (C max )/MIC and AUC/MIC ratios of Ͼ8 and Ն 100, respectively, are predictive of treatment success. Table 2 indicates that, indeed, these values predicted quinolone treatment success in the present experiments. All animals for which the values of both ratios were above the predictive limits responded to therapy. In contrast, for animals for which either the values of one or both of these ratios were below the limits proposed by Andes and Craig (1), the therapy was suboptimal and/or the emergence of resistance was detected. Selection for garenoxacin and levofloxacin resistance in vitro. When large inocula (ca. 5 ϫ 10 9 CFU) of the test isolates of S. aureus and VGS were spread on agar plates containing increasing concentrations of either garenoxacin or levofloxacin, no organisms grew on plates containing drug at a concentration greater than the MIC (frequency, less than 10 Ϫ8 of the original inoculum). For comparison, in retrospective experiments performed with ciprofloxacin, the same organisms grew on plates with the drug at two or more times the MIC at frequencies of Ͼ10 Ϫ8 (15) (16) (17) (18) . Moreover, as indicated in Fig. 4 , stepwise exposure of the bacteria to levofloxacin resulted in the more rapid emergence of organisms with high-level resistance compared with the time of emergence of resistance after stepwise exposure to garenoxacin. Most importantly, ciprofloxacin-resistant grlA mutant MRSA P8-4 was not more likely than its susceptible parent, isolate P8, to develop garenoxacin resistance after multiple passages. All derivatives with decreased quinolone susceptibilities were stable for up to five passages on antibioticfree plates, as determined in tests with 20 individual derivatives randomly isolated from the plates.
DISCUSSION
Garenoxacin is a novel des-fluoro(6)-quinolone with enhanced in vitro activity against gram-positive bacteria. The results of the present study highlight its excellent activity against both staphylococci and VGS. The drug was bactericidal in vitro against all of the test organisms and readily sterilized aortic vegetations in vivo. The latter observation is relevant because endocarditis lesions are therapeutic sanctuaries quasi devoid of cellular and other host defense mechanisms (14) . Hence, the sterilization of vegetations relies almost entirely on the intrinsic ability of the antibacterial drug to kill the bacteria in situ. The present experiments exemplified this phenomenon by showing that levofloxacin was unable to eradicate VGS from the valves but, paradoxically, could sterilize the spleens. This is a classic observation in the endocarditis model, in which macrophages help with bacterial clearance in the spleen but not the valve.
The study compared garenoxacin, levofloxacin, and the standard treatment for endocarditis with cell wall inhibitors. At drug dosages mimicking those used for once-a-day oral administration to humans, the activities of both garenoxacin and levofloxacin were equivalent to those of flucloxacillin and vancomycin against ciprofloxacin-susceptible S. aureus. This result was expected and was consistent with both previous experimental results (17) and the pharmacokinetic and pharmacodynamic parameters that predict successful quinolone therapy suggested by Andes and Craig (1) ( Table 2 ). In addition, the activity of garenoxacin was significantly (P Ͻ 0.05) superior to that of levofloxacin against first-level ciprofloxacin-resistant isolate MRSA P8-4, and against the penicillin-susceptible and penicillin-resistant isolates of VGS. The activity of garenoxacin was also superior to that of ceftriaxone against penicillin-resistant isolate S. mitis 531. Again, this followed the predictions of Andes and Craig (1) ( Table 2) , thus further validating their evaluation system with the model used in the present. Moreover, it underlines the increased efficacy of the new compound both in vitro and in vivo.
In vitro, drug efficacy is defined by parameters such as the MIC, which is determined in standardized medium and under standardized temperature conditions (26) . In vivo, drug efficacy depends on the integration of more complex parameters, including the pharmacokinetic and pharmacodynamic properties of the compound defining the amount of active drug that will be present at the site of infection (10) . One of them is protein binding, which is important for all drug classes. Others are more drug specific and include the time that the concentration is greater than the MIC divided by the MIC for betalactams and macrolides (4, 29) , the peak concentration in the serum divided by the MIC for aminoglycosides (25) , and both the peak concentration divided by the MIC and the AUC divided by the MIC for quinolones (28) . For instance, the quinolone trovafloxacin did relatively poorly against both staphylococci and streptococci in the experimental model of endocarditis not because it was inactive in vitro but, rather, because it was highly bound to plasma proteins (Ն90%) in vivo (18) . The high level of protein binding impeded appropriate diffusion of the drug into the infected foci.
The level of protein binding of garenoxacin in humans is 75% (A. Bello, D. Hollenbaugh, D. Gajjar, L. Christopher, and D. Grasela, Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-45, 2001), whereas that of levofloxacin is 30 to 50% (12, 33) . The different levels of protein binding likely translate into different levels of penetration into tissue in vivo. For instance, while the level of intravegetation penetration of garenoxacin was shown to be ca. 60% of the concentration in serum in the present study, that of levofloxacin was previously reported to be ca. 90% (15) . However, for garenoxacin both its peak level in serum (6.9 mg/liter) and its AUC (58.9 mg ⅐ h/ liter) tended to be higher than those of levofloxacin (5.2 mg/ liter and 47.7 mg ⅐ h/liter, respectively), while the MIC of garenoxacin for the test organisms was lower than that of levofloxacin. Thus, as already observed with S. pneumoniae (Bello et al., 41st ICAAC), the AUC/MIC ratio for unbound garenoxacin compares favorably with that for levofloxacin. This theoretical advantage translates into experimental superiority when the activity of garenoxacin is compared to that of levofloxacin, as in the present study. When the level of penetration into tissue of 60% of the concentration measured in serum after administration of a 400-mg oral daily dose is considered, the concentration of garenoxacin in aortic vegetations still complies with the pharmacokinetic and pharmacodynamic predictions for successful quinolone therapy of Andes and Craig (1), i.e., C max /MIC and AUC/MIC ratios of 8 and Ն100, respectively. Accordingly, garenoxacin still exerted significant therapeutic efficacy against experimental endocarditis. However, the presence of some animals with infected vegetations in the groups infected with P8-4 and VGS suggests that suboptimal pharmacodynamic parameters for garenoxacin against strains in aortic vegetations for which MICs are close to the garenoxacin susceptibility breakpoint of 0.5 mg/liter cannot be excluded (2) . Thus, optimal treatment of infections caused by such organisms might require higher doses of the drug. The finding that garenoxacin can be prescribed at higher doses (for instance, 600 mg/day) without toxicity (21, 32) might provide an adequate margin of safety for its use in humans.
Garenoxacin was much less likely than levofloxacin to select for resistance either in vitro or in vivo. This advantage is shared with other newer quinolones (15) (16) (17) (18) and should become a sine qua none condition for the widespread use of such new compounds. The emergence of ciprofloxacin resistance and, more recently, levofloxacin resistance in community pathogens such as pneumococci (11, 30) is enlightening. It indicates that any leakage in the ability of new antibacterial molecules to hinder FIG. 4 . Selection of quinolone resistance during serial passages of the test staphylococci (A) and streptococci (B) in garenoxacin and levofloxacin. The staphylococci included (i) ciprofloxacin-susceptible MSSA isolate 1112, (ii) ciprofloxacin-susceptible MRSA isolate P8, and (iii) ciprofloxacin-resistant MRSA grlA mutant P8-4. The streptococci comprised penicillin-susceptible isolate S. oralis 226 and penicillin-resistant isolate S. mitis 531.
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on July 9, 2017 by guest http://aac.asm.org/ resistance carries the risk of loosing them for clinical application. Hence, the toll for the selection of resistance to one quinolone is loss of the whole family of quinolones at once. In summary, the present observations highlight the excellent in vitro activities of garenoxacin against staphylococci and streptococci expressing a number of unrelated resistance phenotypes. They add to other experimental work indicating the good efficacy of garenoxacin against experimental pneumococcal meningitis (9, 27) . These results were achieved with pharmacokinetics that simulate those achieved in humans after administration of oral doses of the drug. Thus, they suggest that garenoxacin may be considered for outpatient treatment of severe S. aureus and VGS infections.
